Rheumatology
Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.
Recent Discussions
How would you approach immunosuppression in a patient with well-controlled HIV and RF+ rheumatoid arthritis breaking through hydroxychloroquine with ongoing inflammation confirmed on ultrasound?
There is a reasonable amount of literature on this topic. The consensus is that if ongoing HAART therapy is effective at controlling viral load and maintained, Methotrexate and TNF antagonists are well tolerated; they do not seem to affect HIV viral load. The safety of JAK inhibitors, leflunomide, a...
Should the use of avacopan be limited to those patients at increased risk of steroid toxicity given the anticipated high cost of this medication?
Once Avacopan is available for clinical use in the treatment of patients with AAV, providers will need to carefully weigh risks and benefits of the medication while considering other factors including cost.The ADVOCATE trial used a novel glucocorticoid toxicity index that captures common GC-related ...
Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?
Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...
In patients with anti-PL7 antibody–associated antisynthetase syndrome, can sacroiliitis occur as part of the inflammatory arthritis spectrum, or should alternative causes be considered?
A review of the literature on large cohorts of antisynthetase syndrome does not report sacroiliitis as a feature, but rather, inflammatory arthritis similar to rheumatoid arthritis (with or without RF and CCP) is described. Therefore: It is important to confirm whether the PL-7 result is truly posi...
How do you approach the management of inflammatory arthritis in a patient with Sjogren’s disease who is unable to tolerate or take methotrexate, leflunomide, or hydroxychloroquine?
Would consider a B-cell targeted agent. Currently, rituximab which was included in the 2017 MSK and biologic guidelines (Carsons et al., PMID 27390247) for SjD inflammatory arthritis.Serum level of BAFF is elevated in SjD, so an anti-BAFF agent, like belimumab, could be considered.Have avoided use o...
What approaches can we take to initiate therapy and improve survival rates in patients with HLH?
At our institution, we have comprised a multidisciplinary team to help treat these patients. The team or "HLH task force" as we like to call ourselves is comprised of a clinical immunologist, rheumatologist, dermatologist, critical care physician, hepatologist, BMT attending/hematologist, infectious...
Do you offer antibiotic therapy for patients with a chronic joint infection, with no plans for surgery, and with an open draining sinus tract?
This is a complex question that requires a nuanced answer. I am assuming this is a periprosthetic joint infection. If so, why is there no plan for surgical intervention—is this because the patient’s care is comfort-focused? How old is the patient? What is the microbial etiology, and is it even amena...
How do you manage patients with scleroderma who present with finger ulcerations without other signs of soft tissue infection and MRI demonstrates potential concern for osteomyelitis?
I think this is a tricky situation. Sometimes there is bone damage from acro-osteolysis from the ischemic injury of the scleroderma itself, which can sometimes be difficult to distinguish from osteomyelitis. I would consider watching closely for other signs of deeper infection. You could also consid...
How long would you recommend that a patient continues guselkumab prior to deciding that the therapy is not effective?
Many trials have a placebo-controlled period of 12-24 weeks. Thereafter, all patients receive active treatment. Even if the original treatment allocation remains unknown to the patient and doctor, they know that from that moment on, everyone receives active treatment. This will have an influence on ...
Would you give a trial of immunosuppression in a patient with previously diagnosed IPF who now comes to you with moderate titer ANA and history of discoid lupus but no other clear systemic features or lab abnormalities suggestive of SLE?
No, I would not automatically RX immunosuppressants in this clinical scenario, which has numerous facets to it that do need to be addressed: The treatment for progressive idiopathic pulmonary fibrosis (IPF) is an antifibrotic, not an immunosuppressant. I ALWAYS manage my SLE-pulmonary patients with ...